Repeated Cycles of Recombinant Human Interleukin 7 in HIV-Infected Patients with Low CD4 T-Cell Reconstitution on Antiretroviral Therapy: Results of 2 Phase II Multicenter Studies

Clinical Infectious Diseases

Volumn 62, Issue 9, 2016, Pages 1178-1185

  Thiebaut, Rodolphe ^a   Jarne, Ana ^a   Routy, Jean Pierre ^d   Sereti, Irini ^e   Fischl, Margaret ^g   Ive, Prudence ⁱ   Speck, Roberto F ^k   D'Offizi, Gianpiero ^l   Casari, Salvatore ^m   Commenges, Daniel ^a   Foulkes, Sharne ^j   Natarajan, Ven ^f   Croughs, Therèse ^b   Delfraissy, Jean François ^b   Tambussi, Guiseppe ⁿ   Levy, Yves ^c   Lederman, Michael M ^h  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^d MCGILL UNIVERSITY   (Canada)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^h CASE WESTERN RESERVE UNIVERSITY   (United States)

ⁱ Clinical HIV Research Unit   (South Africa)

^j JOSHA Research   (South Africa)

^k UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^l NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^m Infectious and Tropical Diseases Unit   (Italy)

ⁿ SAN RAFFAELE HOSPITAL   (Italy)

more..

Author keywords

CD4; HIV; immune restoration; Interleukin 7; T cell recovery

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DRUG ANTIBODY; INTERLEUKIN 7; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RECOMBINANT PROTEIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; MIDDLE AGED; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TREATMENT DURATION; CLINICAL TRIAL; DRUG EFFECTS; HIV INFECTIONS; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HIV; HIV INFECTIONS; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-7; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84966539095     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw065     Document Type: Article

References (20)

1. Bonnet F, Chene G, Thiebaut R, et al. Trends and determinants of severe morbidity in HIV-infected patients: the ANRS CO3 Aquitaine Cohort, 2000-2004. HIV Med 2007; 8:547-54.
2. Mocroft A, Furrer HJ, Miro JM, et al. The incidence of AIDS-defining illnesses at a current CD4 count ? 200 cells/?L in the post-combination antiretroviral therapy era. Clin Infect Dis 2013; 57:1038-47.
3. Lewden C, Chene G, Morlat P, et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007; 46:72-7.
4. Young J, Psichogiou M, Meyer L, et al. CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. Plos Med 2012; 9:e1001194.
5. May MT, Gompels M, Delpech V, et al. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy: UK cohort study. AIDS 2014; 28:1193-202.
6. Gilson RJC, Man S-L, Copas A, et al. Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med 2010; 11:152-60.
7. O'Connor JL, Smith CJ, Lampe FC, et al. Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppression. AIDS 2014; 28:919-24.
8. Mocroft A, Lundgren JD, Sabin ML, et al. Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the collaboration of observational HIV epidemiological research Europe study (COHERE). PLoS Med 2013; 10:e1001510.
9. Pantaleo G, Lévy Y. Vaccine and immunotherapeutic interventions. Curr Opin HIV AIDS 2013; 8:236-42.
10. Sereti I, Dunham RM, Spritzler J, et al. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 2009; 113:6304-14.
11. Levy Y, Lacabaratz C, Weiss L, et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 2009; 119:997-1007.
12. Levy Y, Sereti I, Tambussi G, et al. Effects of r-hIL-7 on T cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo controlled, multicenter study. Clin Infect Dis 2012; 55:291-300.
13. Thiebaut R, Drylewicz J, Lacabaratz C, Sekaly R, Lederman MM. Quantifying and predicting the effect of exogenous interleukin-7 on CD4+ T cells in HIV-1 infection. 2014; 10:e1003630.
14. Sereti I, Estes JD, Thompson WL, et al. Decreases in colonic and systemic inflammation in chronic HIV infection after IL-7 administration. Plos Pathog 2014; 10: e1003890.
15. Younas M, Hue S, Lacabaratz C, et al. IL-7 modulates in vitro and in vivo human memory T regulatory cell functions through the CD39/ATP axis. J Immunol 2013; 191:3161-8.
16. Avettand-Fènoël V, Chaix M-L, Blanche S, et al. LTR real-time PCR for HIV-1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01). J Med Virol 2009; 81:217-23.
17. Rondeau V, Mazroui Y, Gonzalez JR. frailtypack: an R package for the analysis of correlated survival data with frailty models using the penalized likelihood estimation. J Stat Softw 2011; VV:1-26.
18. Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15:893-U92.
19. Zeng M, Smith AJ, Wietgrefe SW, et al. Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections. J Clin Invest 2011; 121:998-1008.
20. Engsig FN, Zangerle R, Katsarou O, et al. Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. Clin Infect Dis 2014; 58:1312-21.